Filing and business context
Identity discrepancy: The request identifies Enveric Biosciences, Inc., but the supplied Form 10-Q is for Spatializer Audio Laboratories, Inc. It covers the quarter ended March 31, 2013; the filing was signed May 2, 2013. The filing describes Spatializer as having ceased commercial operations in 2006 and seeking merger, acquisition, or other business-combination opportunities. It does not expect significant operations until a transaction is completed.
Financial results and liquidity
| Metric | Q1 2013 / March 31, 2013 | Comparable period / prior date |
|---|---|---|
| Revenue | $0 | $0 in Q1 2012 |
| General and administrative expense | $4,698 | $4,045 in Q1 2012 |
| Net loss | $4,698 | $4,045 in Q1 2012 |
| Net cash used in operating activities | $12,221 | $12,145 in Q1 2012 |
| Cash and cash equivalents | $1,160 | $1,381 at December 31, 2012 |
| Current liabilities | $30,143 | $25,666 at December 31, 2012 |
| Working capital | Deficit of $24,764 | Deficit of $20,066 at December 31, 2012 |
There was no revenue, so a revenue margin is not meaningful. Current liabilities include $20,000 in loans from stockholders, up from $8,000 at year-end; the filing reports no other debt balance. Stockholders’ equity was a deficit of $24,764. Cash from financing was $12,000 in stockholder loans. No dividends or other material cash-flow sources are reported.
Changes, outlook, and risks
- Quarterly expenses and net loss increased by $653 versus Q1 2012. Operating cash use was slightly higher, while ending cash declined by $221 from December 31, 2012.
- Management said current cash reserves were not sufficient to meet operating obligations for more than two to three months without additional capital, and that the company had no current source of future cash flow. It expected to maintain liquidity only in the short term.
- The filing states that significant operating losses raise substantial doubt about the company’s ability to continue as a going concern. The financial statements include no adjustments for the outcome of that uncertainty.
- In April 2013, the president loaned the company $5,000 interest-free to help fund operating expenses.
- The company had approximately $9.5 million in federal net operating loss carryforwards, generally available through 2031, subject to an approximately $1 million annual limitation and possible ownership-change limitations.
- Management reported effective disclosure controls and no known material change in internal control over financial reporting during the quarter. It disclosed no legal proceedings expected to have a material adverse effect, while noting litigation uncertainties.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Spatializer Audio Laboratories, Inc., not Enveric Biosciences, Inc.
- Reconcile cash: the financial statements report $1,160 at March 31, 2013, but one MD&A passage says $1,060. The balance sheet and cash-flow statement both report $1,160.
- Assess the company’s ability to fund obligations beyond the stated two-to-three-month runway, including whether further insider loans or other financing became available.
- Review the terms and repayment status of stockholder loans and the effect of any proposed merger, acquisition, or ownership change on the tax-loss carryforwards.